Skip to contentI
IGC Pharma, Inc.
I
IGCIGC Pharma, Inc. Q4 2019 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$1.54M$1.54Mderived+34.9% vs Q4 2018 Net Income-$1.58M-$1.58MderivedN/M vs Q4 2018 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IGC Pharma, Inc. · CIK 1326205 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$27,000— Operating Incomederived-$1,699,000N/M Operating Cash Flowderived-$1,148,000N/M Free Cash Flowderived-$1,156,000N/M Margins · derivedGross margin1.8%
Operating margin-110.2%−52.7 pt vs Q4 2018
Net margin-102.3%−57.1 pt vs Q4 2018
ended Mar 31, 2019 · filed Jun 14, 2019 · 75 d after period end